The abstract is read at the publisher; the summary is JClub's.
GradientScreen, a microfluidic ratiometric combination drug screening assay for high-risk paediatric acute lymphoblastic leukaemia, links drug response metrics to clinical outcomes, including MRD.
- Why it matters: Clinically actionable functional screens that are easy to adopt are limited, despite the need for personalized strategies in high-risk paediatric ALL.
- What they did: The assay generates overlapping drug gradients on a microfluidic device and uses an analysis framework to quantify ratiometric synergy and efficacy, with partial least squares regression to relate metrics to outcomes.
- The result: Combination response metrics correlate with MRD after treatment initiation and later clinical end-points, and the system can evaluate experimental regimens in patients who did not respond to standard treatment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.